Rhythm Pharmaceuticals, Inc. (RYTM)

Revenue

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Product Revenue, Net	239.92M	194.77M	130.13M
License Revenue	-	-5.01M	-
Revenue (Total)	239.92M	189.76M	130.13M

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
License Revenue	-	-5.01M	-
United States Revenue	165.08M	133.55M	96.11M
International Revenue	-	-	34.02M
Revenue (Other)	74.84M	61.22M	-
Revenue (Total)	239.92M	189.76M	130.13M

Data Source: Fiscal.ai Last updated: Aug 4, 2026

Financial data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 2, 2026

Data Sources Report a data error